Skip to main content
Premium Trial:

Request an Annual Quote

Edward Tenthoff Joins Piper Jaffray as Senior Analyst; Frank Jones to Chair InforSense Board; Robert Hennessey Steps Down as Chair of Genome Therapeutics; and Others

NEW YORK, May 14 - Edward Tenthoff has joined U.S. Bancorp Piper Jaffray as a senior research analyist on the genomics sector, the firm said today. Tentoff comes to Piper Jaffray, of New York, from Think Equity Partners, where he also covered genomics and biotechnology companies. Prior to this, Tentoff covered biotechnology as a senior research analyst at the now-defunct firm Robertson Stephens.

 

At Think Equity, Tenthoff covered a range of companies in the genomics sector, from Applera, Affymetrix, and Amersham to Genaissance and Serologicals.


 

Frank Jones, chairman of oilfield and information services giant Schlumberger Plc, has been appointed non-executive chairman of the InforSense board of directors, the company said May 13.

 

Jones joins the board of InforSense, a London-based discovery informatics provider, with experience serving on other boards, including that of Sema Group Plc. He is a veteran of the IT industry, the company said.


 

Muzammil Mansuri, executive-in-residence at Flagship Ventures, has been appointed to the scientific advisory board of Achillion Pharmaceuticals, a company developing small-molecule drugs for infectious disease resistance, the company said May 12.

 

Mansuri is currently chairman of Beyond Genomics, and a director and executive chairman of Adaptive Therapeutics. He has previously served as executive vice president and Chief Operating Officer at GPC Biotech. Between 1994 and 2000, Mansuri also held executive positions at Mitotix. Prior to this time, he worked in chemistry at Bristol-Myers Squibb. 


 

Anthony Shuber, executive vice president and chief technology officer at Exact Sciences, has been awarded the "90 in 9" science award by the Colorectal Cancer Network. The award is designed to recognize a person who has contributed to the organization's goal of having 90 percent of people who are at risk for colorectal cancer screened by 2010. Exact Sciences, which Shuber co-founded, has developed the PreGen-Plus screening technology for colorectal cancer.


 

Robert Hennessey has stepped down as chairman of the board of directors at Genome Therapeutics, after completing a nine-year term. He will remain on the board of the company, the company said May 9. Steven Rauscher, the company's president and CEO, will now serve also as Chairman.

 

Hennessey has previously served as president of Genome Therapeutics, from 1993 to 2000.


 

Lion Biosciences has tapped former Spotfire executive Joseph Donahue president, putting him in charge of Lion's north American operations, the company said May 8.

 

At Spotfire, Donahue was vice president of global life sciences and chemicals markets, where he was responsible for the direction of the firm's sales and marketing strategy. Before joining Spotfire, Donahue was vice president of north American sales at MDL Information Systems.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.